Choose your preferred way to stay informed of new case launches and settlement deadlines
The filed complaint alleges that Gilead Sciences, Inc. made materially false and/or misleading statements and/or failed to disclose that: Gilead issued a press release on June 10, 2025, announcing that "[t]he U.S. Food and Drug Administration has placed a clinical hold on Gilead's HIV treatment trials of GS-1720 (an investigational integrase strand transfer inhibitor) and/or GS-4182 (an investigational capsid inhibitor)[,]" specifying that "[t]he clinical hold is due to the identification of a safety signal of decreases in CD4+T-cell (CD4) and absolute lymphocyte counts in a subset of participants receiving the combination of GS-1720 and GS-4182." Following this news, Gilead's stock price fell over 2% on the same day.
In order to be eligible to join the GILD class action lawsuit, you must have incurred a loss on shares of Gilead Sciences, Inc. purchased during the class period listed above.
TOP
